GlassScriptPhysician profile
Lacey L Roybal
NPI 1366977027
$8,539.71
in general payments reported to CMS, 2019-2025
31 companies · $1,792 in 2025
The $1,792 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $643 · 2021: $727 · 2022: $709 · 2023: $1,615 · 2024: $1,453 · 2025: $1,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,562 · Education: $297.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,562.36 |
| Education | $297.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,845.25 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,425.62 | 2020-2025 | Tremfya, Simponi, Stelara |
| Novartis Pharmaceuticals Corporation | $948.67 | 2019-2025 | |
| Amgen INC. | $507.65 | 2020-2025 | Otezla, Otezla |
| Lilly USA, LLC | $414.72 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $375.96 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $240.21 | 2019-2024 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $210.70 | 2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $188.03 | 2019-2025 | |
| Organon LLC | $126.13 | 2023-2025 | Vtama, Hadlima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $119.49 | 2019-2021 | |
| Ucb, INC. | $116.60 | 2020-2025 | Bimzelx |
| Biofrontera INC. | $109.38 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $101.85 | 2019-2025 | Nemluvio |
| Dermavant Sciences, INC. | $100.70 | 2022-2024 | Vtama |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $97.33 | 2019 | |
| Pfizer INC. | $96.20 | 2019-2025 | |
| Incyte Corporation | $88.77 | 2022-2023 | Opzelura |
| Sanofi-Aventis U.S. LLC | $72.00 | 2020 | |
| Endo Pharmaceuticals INC. | $67.57 | 2019 | |
| Csl Behring | $55.75 | 2019-2022 | |
| Dermira, INC. | $51.30 | 2019 | |
| Smith+Nephew, INC. | $26.96 | 2023 | Grafix Pl |
| Fresenius Kabi USA, LLC | $23.44 | 2023 | |
| Leo Pharma INC. | $22.86 | 2025 | Anzupgo |
| Vyne Pharmaceuticals INC. | $20.97 | 2021 | |
| Nobelpharma America, LLC | $18.72 | 2025 | |
| Biowound Solutions, INC. | $18.23 | 2025 | Bio-Connekt |
| Takeda Pharmaceuticals U.S.A., INC. | $17.71 | 2023 | Takhzyro |
| Helsinn Therapeutics (U.S.), INC. | $16.05 | 2019 | |
| Mylan Institutional INC. | $14.89 | 2023 | Hulio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Roybal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.